Niusule Biotech Corporation to Present at the Rodman & Renshaw 2010 Annual Global Investment Conference

MONROVIA, CA--(Marketwire - August 30, 2010) - Niusule Biotech Corp. (OTCBB: NIUS) (the Company), a fast growing China-based bio-pharmaceutical company focusing on animal-health products and human nutraceutical supplements, today announced they will present at the Rodman & Renshaw 2010 Annual Global Investment Conference. The conference will be held September 12-15, 2010, at The New York Palace Hotel.

Mr. David Liu from the Company will be speaking on Wednesday, September 15, 2010 at 11:15am Eastern Time in the Kennedy Salon - 4th floor. Additional one-on-one investor meetings will be scheduled in and around the conference.

“We are pleased to be part of the Rodman & Renshaw Conference. As part of our ongoing efforts to widen investor outreach and communicate the Niusule opportunity to existing and new investors, the Rodman conference is an ideal venue to meeting the buy-side,” stated Mr. Liu.

About the 2010 Annual Global Investment Conference
Rodman & Renshaw, LLC will host its 2010 Annual Global Investment Conference in New York from September 12-15, 2010 at the New York Palace. The conference will feature corporate presentations from companies in the following tracks devoted to Healthcare, China, Metals & Mining, Energy, Technology, Cleantech, Community and Regional Banks, and REITs. The Conference will include corporate presentations and Q & A sessions, investor one-on-one meetings and daily networking opportunities.

About Rodman & Renshaw Capital Group, Inc.
Rodman & Renshaw Capital Group is a holding company with a number of direct and indirect subsidiaries, including Rodman & Renshaw, LLC (Rodman) -- a full-service investment bank dedicated to providing corporate finance, strategic advisory and related services to public and private companies across multiple sectors and regions. Rodman also provides research, sales and trading services to institutional investors, and is a leader in the PIPE (private investment in public equity) and RD (registered direct offering) transaction markets.

According to Sagient Research Systems, Rodman has been ranked the #1 Placement Agent in terms of deal volume of PIPE and RD financing transactions completed every year since 2005. For more information on Rodman & Renshaw, visit www.rodm.com.

About Niusule Biotech Corp.
Niusule Biotech Corp. is a bio-pharmaceutical company dedicated to offering high-quality pharmaceutical and nutritional supplement products to enhance both animal and human health. The Company has recently acquired a majority interest in Tianjin Behigh Pharmaceutical Co., Ltd, a veterinary drug and feed additives manufacturing company that produces injections, tablets, granules, oral solutions, powder and disinfectant for animal use. For the human product line, Niusule currently has a retail distribution network throughout China comprised of 124 outlets at high-end supermarkets and shopping malls in Zhejiang province, Shanghai and Beijing. For more information about Niusule Biotech Corp., please visit www.niusule.com.

Forward Looking Statements
This news release contains certain “forward-looking statements.” Forward-looking statements are based on current expectations and assumptions and are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified, and many of which are beyond the Company’s control. The forward-looking statements are also identified through the use of words “believe,” “enable,” “may,” “will,” “could,” “intends,” “estimate,” “anticipate,” “plan,” “predict,” “probable,” “potential,” “possible,” “should,” “continue,” “project,” “expect” and other words of similar meaning. Actual results could differ materially from these forward-looking statements as a result of a number of risk factors detailed in the Company’s periodic reports filed with the SEC. Given these risks and uncertainties, investors are cautioned not to place undue reliance on such forward-looking statements and no assurances can be given that such statements will be achieved. Niusule Biotech Corp. does not assume any duty to publicly update or revise the material contained herein.